Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.46 |
| ▸ | FLT1 | P17948 | 4/20 | 0.46 |
| ▸ | FLT4 | P35916 | 4/20 | 0.46 |
| ▸ | PARP1 | P09874 | 4/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.41 |
| ▸ | MLKL | Q8NB16 | 2/20 | 0.41 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4811712 | 0.91 | KDR (0.46) | KDRFLT1FLT4PARP1RIPK1 | |
| SCHEMBL4805956 | 0.85 | KDR (0.55) | KDRRIPK1MLKLRIPK3AURKA | |
| SCHEMBL4812736 | 0.83 | KDR (0.52) | KDRFLT1FLT4PARP1RIPK1 | |
| SCHEMBL4805030 | 0.77 | KDR (0.55) | KDRRIPK1MLKLRIPK3AURKA | |
| SCHEMBL4814935 | 0.74 | KDR (0.72) | KDRRIPK1MLKLRIPK3AURKA | |
| SCHEMBL30629807 | 0.74 | KDR (0.51) | KDRFLT1FLT4PARP1RIPK1 | |
| SCHEMBL26114981 | 0.74 | KDR (0.51) | KDRFLT1FLT4PARP1RIPK1 | |
| SCHEMBL31672483 | 0.73 | KDR (0.65) | KDRFLT1FLT4PARP1RIPK1 | |
| SCHEMBL10151190 | 0.73 | KDR (0.65) | KDRFLT1FLT4PARP1RIPK1 | |
| SCHEMBL5226379 | 0.73 | KDR (0.41) | KDRFLT1FLT4PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459455-B2 | Pyrimidine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-02 | — | — | US | claimed |
| US-20050085637-A1 | Antiproliferative agents; angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-04-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085637-A1 | Antiproliferative agents; angiogenesis inhibitors | TIE1, TEK, KDR | KDR 3/4885FLT1 4/4885FLT4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.